Current News

Contact | Print version | PDF version | Send article | RSS feed

Daiichi Enters Funded Research Agreement With Cyntellect

01 Apr 2005 - Cyntellect, Inc., a privately-held biotechnology company, announced the company has entered into a research agreement with Daiichi Pharmaceutical Co., Ltd. ("Daiichi") to utilize Cyntellect's high-throughput cell imaging and laser-based cell manipulation technology, LEAP(TM), for novel drug discovery.
 
Under the terms of the collaboration, Cyntellect will design, configure and run LEAP cell-based assays against a compound collection provided by Daiichi. Specific financial terms were not disclosed.
 
"We are pleased to establish a formal research relationship with Daiichi, one of Japan's leading pharmaceutical companies," stated Dr. Fred Koller, President and CTO. "Daiichi's commitment to Cyntellect and LEAP represents another important validation of our technology and highlights the unique value proposition presented by combining imaging and cell manipulation in the process of discovering new therapeutics."